UNIVERSITY OF WASHINGTON
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic
- Conditions
- Online Therapy
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 818
- Registration Number
- NCT04360850
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Treatment for COVID-19 in High-Risk Adult Outpatients
- Conditions
- SARS-CoV-2COVID-19
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 289
- Registration Number
- NCT04354428
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Tulane University, New Orleans, Louisiana, United States
🇺🇸University of Washington Coordinating Center, Seattle, Washington, United States
Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Behavioral: Sleep Innovations for Preschoolers with Arthritis (SIPA)
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 12
- Registration Number
- NCT04354337
- Locations
- 🇺🇸
University of washington, Seattle, Washington, United States
Simplifying Treatment and Monitoring for HIV (STREAM HIV)
- Conditions
- HIV/AIDSHIV-1-infection
- Interventions
- Combination Product: Point-of-care viral load testing and tenofovir adherence testing
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 539
- Registration Number
- NCT04341779
- Locations
- 🇿🇦
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
- Conditions
- Prostate AdenocarcinomaBiochemically Recurrent Prostate Carcinoma
- Interventions
- Biological: DurvalumabDrug: OlaparibOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 6
- Registration Number
- NCT04336943
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Kidney Precision Medicine Project
- Conditions
- Acute Kidney FailureAcute Renal InjuryKidney Failure, AcuteKidney Insufficiency, AcuteRenal Failure, AcuteAcute Renal InsufficiencyChronic Kidney InsufficiencyAcute Kidney InsufficiencyKidney Insufficiency, ChronicAcute Renal Failure
- Interventions
- Procedure: Kidney Biopsy
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1000
- Registration Number
- NCT04334707
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Texas at Southwestern, Dallas, Texas, United States
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8
- Interventions
- Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA VaccineDrug: PaclitaxelBiological: TrastuzumabBiological: Pertuzumab
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 16
- Registration Number
- NCT04329065
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
- Conditions
- SARS-CoV-2SARS (Severe Acute Respiratory Syndrome)COVID-19Corona Virus Infection
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 943
- Registration Number
- NCT04328961
- Locations
- 🇺🇸
University of Washington, Coordinating Center, Seattle, Washington, United States
🇺🇸Tulane, New Orleans, Louisiana, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
Two-way Texting for VMMC Follow-up in Republic of South Africa
- Conditions
- Voluntary Medical Male Circumcision
- Interventions
- Behavioral: Text-based VMMC follow-up
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1093
- Registration Number
- NCT04327271
- Locations
- 🇿🇦
Mogwase, Mogwase, Bojanala, South Africa
🇿🇦Bafokeng, Phokeng, Bojanala, South Africa
🇿🇦Tsakane Clinic, Brakpan, Gauteng, South Africa
NIH Release/Relock Socket
- Conditions
- Lower Limb Amputation Below Knee (Injury)
- Interventions
- Device: Release/Relock Socket - In LabDevice: Release/Relock Socket - Out of LabDevice: Release/Relock Socket & Control
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 100
- Registration Number
- NCT04305782
- Locations
- 🇺🇸
University of Washington Bioengineering, Seattle, Washington, United States